We’ve had the disappointing news that MS drug ocrelizumab won’t be made available for primary progressive MS. The National Institute of Health and Care Excellence (NICE), who approve drugs to be available on the NHS in England and Wales, announced their decision on 10 September.

What is ocrelizumab and why does this decision matter?

Ocrelizumab (brand name Ocrevus) is a drug that has a Europe-wide license to treat relapsing MS and early primary progressive MS. It’s taken as an infusion.

We’re upgrading MS Society email - find out why, how and when.

We want to ensure that we’re providing the best possible support for people living with MS.

Our MS community is hugely diverse. Together we campaign for change, provide support and information, and drive forward progress in research. Our ultimate goal is to stop MS.

And to do this we want to transform our membership to be as inclusive and relevant to as many people in the MS community as possible.

Michelle Mitchell, our Chief Executive, will be leaving the MS Society at the end of October to take up the position of CEO of Cancer Research UK.

Michelle has been with us since 2013 and has made a huge contribution in that time. Thanks to her vision, energy and expertise, we’ve made great strides towards our mission through a renewed focus on the things that matter most to people with MS. We’ve benefited greatly from Michelle’s determination to increase our impact and make every penny of our donors’ money count by working creatively, efficiently and at pace.